ReCore

California Regional Multiple Listing Service (CRMLS) Announces Flagship MLS Platform Perchwell Begins Beta Phase for Agents and Brokers

Retrieved on: 
수요일, 12월 20, 2023
Element, Partnership, ReCore, Software, MLS, API, Chocolate liquor, Real estate

CHINO HILLS, Calif., Dec. 20, 2023 /PRNewswire/ -- California Regional MLS (CRMLS), the largest and most recognized MLS in the country, is announcing Perchwell's beta launch for a select group of users. The flagship MLS platform, which includes both desktop and mobile apps, will power and streamline real estate professionals' core workflows more efficiently than ever before.

Key Points: 
  • The flagship MLS platform, which includes both desktop and mobile apps, will power and streamline real estate professionals' core workflows more efficiently than ever before.
  • Perchwell will also be made available to non-CRMLS brokerages and MLSs throughout California via real estate technology company REcore in 2024.
  • Perchwell will support day-to-day real estate activities, including listing submission and syndication, property searching, market analysis, client collaboration, and more.
  • Unlike legacy platforms, Perchwell features a property-centric data model allowing it to serve as the MLS' single source of comprehensive listing information.

Sofinnova Partners Enhances Leadership in Medtech Acceleration with Key Appointments

Retrieved on: 
월요일, 11월 13, 2023
Professional Services, Medical Devices, Health, Finance, Fintech, Biotechnology, Acceleration, MD, FDA, ReCore, Pharmaceutical industry, Sofinnova, Partner

These appointments reflect the success of Sofinnova’s medtech accelerator and highlights the firm’s strong conviction in the opportunities still untapped within the medtech sector.

Key Points: 
  • These appointments reflect the success of Sofinnova’s medtech accelerator and highlights the firm’s strong conviction in the opportunities still untapped within the medtech sector.
  • Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said: "These appointments mark a strategic bolstering of our team and underscore the solid performance and promising trajectory of our medtech acceleration strategy.
  • Mano Iyer, Partner at Sofinnova Partners, said: "My journey in early stage medtech and venture hit its stride here at Sofinnova over fifteen years ago.
  • Both appointments are effective immediately, further positioning Sofinnova Partners at the forefront of medtech innovation and acceleration.

TCT 2023: The Efficacy and Safety of the SMART Trial Presented by World Renowned Expert

Retrieved on: 
금요일, 11월 10, 2023
Hypertension, Safety, SAN, RDN, Patient, ReCore, TCT, Sympathetic, Pharmaceutical industry, Medtronic

The joint SMART Study Investigators-Felix Mahfoud presentation attracted substantial interest and admiration from the audience at the conference.

Key Points: 
  • The joint SMART Study Investigators-Felix Mahfoud presentation attracted substantial interest and admiration from the audience at the conference.
  • The SMART Study enrolled 220 patients with uncontrolled hypertension at a 1:1 ratio into msRDN and Sham groups between November 2016 and February 2022.
  • The results demonstrated the safety and efficacy of renal msRDN to treat uncontrolled hypertension via only four ablations on each side of the renal main artery.
  • Given this context, RDN was one of the central themes and most hotly pursued topics during the TCT conference this year.

Otsuka Medical Devices and Recor Medical Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
수요일, 11월 8, 2023
Medical Devices, FDA, Health, Clinical Trials, General Health, Cardiology, JAMA, ReCore, Food, Physician, Blood pressure, American Medical Association, News, Medical device, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Overactive bladder, RDN, Patient, Pharmaceutical industry

Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and Recor Medical, Inc. (“Recor”, subsidiary of Otsuka Medical Devices) announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and Recor Medical, Inc. (“Recor”, subsidiary of Otsuka Medical Devices) announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient’s blood pressure.
  • It is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.
  • The Paradise system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through each of the main renal arteries to the surrounding nerves.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
수요일, 11월 8, 2023
Biotechnology, FDA, Medical Devices, Health, Cardiology, JAMA, ReCore, Harvard Medical School, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Overactive bladder, Diabetes, RDN, Patient, Associate, Pharmaceutical industry, Endocrinology, Medicine, Brigham

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient’s blood pressure.
  • The Paradise system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through each of the main renal arteries to the surrounding nerves.
  • The Paradise Ultrasound RDN system previously received CE mark and has been successfully introduced in Europe and is an investigational device in Japan.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
수요일, 11월 8, 2023
JAMA, FDA, Harvard Medical School, Brigham and Women's Hospital, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Treatments for overactive bladder, Diabetes, RDN, Patient, Hospital, Associate, Pharmaceutical industry, ReCore, Endocrinology, Medicine

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.
    PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient's blood pressure.
  • The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
  • Recor has been focused on developing and testing the Paradise Ultrasound RDN system for the treatment of hypertension since 2009.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
수요일, 11월 8, 2023
JAMA, FDA, Harvard Medical School, Brigham and Women's Hospital, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Treatments for overactive bladder, Diabetes, RDN, Patient, Hospital, Associate, Pharmaceutical industry, ReCore, Endocrinology, Medicine

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.
    PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient's blood pressure.
  • The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
  • Recor has been focused on developing and testing the Paradise Ultrasound RDN system for the treatment of hypertension since 2009.

NorthstarMLS Launches New SSO Dashboard

Retrieved on: 
목요일, 10월 19, 2023
Single sign-on, ReCore, Software, Engineering, SSO, Chocolate liquor, Marketing, MLS, Medical device

CHINO HILLS, Calif., Oct. 19, 2023 /PRNewswire/ -- Following the announcement of a Single Sign On (SSO) technology agreement in May 2023 between California Regional MLS (CRMLS) and NorthstarMLS, today NorthstarMLS launched the SSO dashboard created by CRMLS for its 22,000 subscribers.

Key Points: 
  • CHINO HILLS, Calif., Oct. 19, 2023 /PRNewswire/ -- Following the announcement of a Single Sign On (SSO) technology agreement in May 2023 between California Regional MLS (CRMLS) and NorthstarMLS, today NorthstarMLS launched the SSO dashboard created by CRMLS for its 22,000 subscribers.
  • A component of the REcenterhub platform, the new dashboard offers a modernized MLS experience, with intuitive navigation and easy-to-use features.
  • "REcenterhub and the SSO dashboard is one of our most recent — and elaborate — innovations to date," said Art Carter, CEO of CRMLS.
  • "We see the SSO dashboard as an opportunity to provide NorthstarMLS subscribers with faster, easier, and more secure access to their real estate marketplace," said NorthstarMLS CEO Tim Dain.

ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension

Retrieved on: 
금요일, 7월 14, 2023
Health, FDA, Medical Devices, Health Technology, Pharmaceutical, Cardiology, Biotechnology, Blood pressure, CE, European Renal Association, Food, ReCore, SOLO, RDN, ERA, Journal, PMA, Patient, European Society for Medical Oncology, International Society on Hypertension in Blacks, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, International Society, Pharmaceutical industry, Medicine, Hypertension

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.

Key Points: 
  • ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.
  • The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.
  • Current rates of treatment and control of hypertension remain suboptimal, and the ESH guidelines assist clinicians and patients in achieving the goal of better health.
  • “Recommendation of renal denervation by the recently published European Society of Hypertension (ESH) 2023 Guidelines is a significant milestone for the field of arterial hypertension management.

Sofinnova Partners Welcomes Mano Iyer as Venture Partner

Retrieved on: 
목요일, 1월 5, 2023
Professional Services, Health, Medical Devices, Other Science, Finance, General Health, Science, ReCore, Teleflex, MD, Multimedia, U.S. Venture Partners, MBA, CMI, Partner, Medtronic, Engineering, Arrow, Medical device, Medical imaging, Video game, Stanford University, Sofinnova

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Manohar (Mano) Iyer, a serial entrepreneur with longstanding ties to Sofinnova, as Venture Partner.

Key Points: 
  • Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Manohar (Mano) Iyer, a serial entrepreneur with longstanding ties to Sofinnova, as Venture Partner.
  • Mr. Iyer founded ReCor Medical during his time as an Entrepreneur-in-Residence at Sofinnova Partners in 2009.
  • Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “We are delighted to have Mano back in the fold at Sofinnova Partners.
  • The trio (Hascoët, Lenihan, Iyer) joined forces with Antoine Papiernik and, with the backing of Sofinnova Partners, founded MD Start to create and incubate innovative medical device companies.